Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several ...
In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...
In plain language. Written by scientists. For the global HD community.
On December 3, 2024 we received word that the very first person received a new drug, called ALN-HTT02, as part of a Phase 1 trial aiming to treat Huntington’s disease (HD). Going boldly as the first ...
Ed is a neurologist at the National Hospital for Neurology and Neurosurgery, London, UK, and a Professor of Neurology at University College London where he is Associate Director of the Huntington’s ...
Michael is a consultant neurologist in the department of neurology at the University of Ulm in Germany, and scientific projects manager for the European Huntington’s disease network. Michael trained ...
Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community. With your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback